This thought leadership article explores the increase in antimicrobial-resistant infections such as C diff due to the high volume of patients being treated in hosipitals for COVID-19.

This article is taken from European Biopharmaceutical Review October 2020, pages 12-14. © Samedan Ltd.

Read article